Can a High-Fat drink help Alzheimer's? small study tests safety

NCT ID NCT02912936

Completed Symptom relief Sponsor: University of British Columbia Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a ketogenic drink made from medium chain triglycerides (MCTs) in 43 people with Alzheimer's disease or a type of frontotemporal dementia. The goal was to see if it was safe and tolerable, and to measure ketone levels in the blood. It was a small, early-stage trial focused on safety, not on whether the drink improves symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ketogenic medium chain triglyceride (MCT) drink
What this could lead to: If it works, this could point toward a dietary supplement that helps manage symptoms in Alzheimer's or related dementias by providing an alternative brain fuel.
What could go wrong: This is a very early, small pilot study focused on safety and tolerability, not effectiveness. The results may not apply to all patients, and any benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease frontotemporal dementia Ketosis progressive non-fluent aphasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER'S DISEASE FRONTOTEMPORAL DEMENTIA (FTD) PRIMARY PROGRESSIVE NON-FLUENT APHASIA

Contacts and locations

Locations

Djavad Mowafaghian Centre for Brain Health

Vancouver, British Columbia, V6T 1Z3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.